Negative PCR for SARS‐CoV‐2 on respiratory samples at day 14 from enrolmentd · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in negative PCR for SARS‐CoV‐2 on respiratory samples at day 14 from… compared with standard care or placebo (low certainty).
1 finding from 1 review
Progression to mechanical ventilation · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in progression to mechanical ventilation compared with standard care or placebo (moderate certainty).
1 finding from 1 review
Time to clinical improvement · adults with mild to severe COVID‐19
It is very uncertain whether hydroxychloroquine (HCQ) changes time to clinical improvement compared with standard care or placebo (very low certainty).
1 finding from 1 review
Participants with any adverse events · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with standard care or placebo (moderate certainty).
1 finding from 1 review
Participants with serious adverse events · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in participants with serious adverse events compared with standard care or placebo (low certainty).
1 finding from 1 review
Participants with prolongation of QT‐interval on ECG · adults with mild to severe COVID‐19
It is very uncertain whether hydroxychloroquine (HCQ) changes participants with prolongation of QT‐interval on ECG compared with standard care or placebo (very low certainty).
1 finding from 1 review
Development of confirmed COVID‐19 at 14 days from enrolment · people who have been exposed to SARS‐CoV‐2
It is very uncertain whether hydroxychloroquine (HCQ) changes development of confirmed COVID‐19 at 14 days from enrolment compared with placebo (very low certainty).
1 finding from 1 review
Hospitalized due to COVID‐19c · people who have been exposed to SARS‐CoV‐2
It is very uncertain whether hydroxychloroquine (HCQ) changes hospitalized due to COVID‐19c compared with placebo (very low certainty).
1 finding from 1 review
Relapse · people with multiple sclerosis
It is very uncertain whether siponimod changes number of participants with relapses at 6 months compared with placebo (very low certainty).
1 finding from 1 review
Disability worsening · people with multiple sclerosis
Siponimod may leads to lower participants with disability worsening at 6 months compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with multiple sclerosis
Siponimod showed no clear difference in number of participants who withdrew due to AEs at 6 months compared with placebo (low certainty).
1 finding from 1 review
Annualised relapse rate · people with multiple sclerosis
Siponimod may leads to lower annualised relapse rate compared with placebo (low certainty).
1 finding from 1 review
Mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI image at 6 months · people with multiple sclerosis
It is very uncertain whether siponimod changes mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI… compared with placebo (very low certainty).
1 finding from 1 review
Mean number of new lesions or enlarged pre‐existing lesions on T2‐weighted brain MRI images at 6 months · people with multiple sclerosis
Siponimod may leads to lower mean number of new lesions or enlarged pre‐existing lesions on… compared with placebo (low certainty).
1 finding from 1 review
SAEs · people with multiple sclerosis
Siponimod showed no clear difference in number of participants with at least one SAE at 6 months compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · CVD (ASCVD, HF, or both)
DPP4i showed no clear difference in cardiovascular mortality compared with placebo (high certainty).
1 finding from 1 review
Cardiovascular mortality · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower cardiovascular mortality compared with placebo (high certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · CVD (ASCVD, HF, or both)
GLP‐1RA showed no clear difference in myocardial infarction (fatal or non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower stroke (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review